G. Sheikh

PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer

Minglun Li, M. Unterrainer, P. Rogowski, 2024, EJNMMI reports.

Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [177Lu]Lu-PSMA-I&T Therapy

G. Böning, M. Zacherl, L. Unterrainer, 2024, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

K. Jurkschat, R. Tiling, P. Bartenstein, 2022, Frontiers in Oncology.

Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients

C. Cyran, M. Fabritius, C. Schmid-Tannwald, 2023, European radiology.

Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients

C. Cyran, C. Auernhammer, C. Spitzweg, 2023, European Radiology.